louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02199119: Effect of Television Viewing and Exercise on Appetite, Satiety, and Food Intake in Children
Official title: Effect of Television Viewing During Exercise on Subjective Appetite, Satiation, and Food Intake in 9 to 14 Year Old Children
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Childhood Obesity
Keywords: children
television
exercise
food intake
appetite
satiation
Lead sponsor: Toronto Metropolitan University
Sponsor class: OTHER
First posted: 2014-07-24
Enrollment: 13
Sex: ALL
Minimum age (years): 9
Maximum age (years): 14
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The purpose of this study was to describe the effect of 30 min TV viewing with or without simultaneous moderate exercise using a treadmill on subsequent subjective appetite, satiation, and food intake in normal weight 9 to 14 year old children. It is hypothesized that TV viewing during exercise immediately before mealtime affects food intake regulation through its effect on the control of appetite and satiation.


Eligibility criteria: Inclusion Criteria:

* overall healthy, normal weight (between the 5th and 85th BMI percentile for age and gender) 9 to 14 year old boys and girls (peripubertal) born at term and at a normal birth weight, and does not receive any medications

Exclusion Criteria:

* significant learning, behavioral, or emotional difficulties, restricted diet, food allergies to test treatments

Primary outcomes:
measure: Food Intake kcal
timeFrame: 30 min after end of treatment
Secondary outcomes:
measure: Subjective appetite and satiation in mm
timeFrame: measured at time 0, 15, 30, and 60 min
Other outcomes:
Locations:
city: Toronto
country: Canada
facility: FIRST Lab, Ryerson University
state: Ontario
Study officials:
affiliation: Toronto Metropolitan University
name: Nick Bellissimo, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01368419: Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Official title: Phase II Study of Continuous Endostar Infusion Combined With Radiotherapy in Esophageal Cancer Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
Conditions: Esophageal Cancer
Keywords: Endostar
Radiotherapy
Esophageal Cancer
Lead sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd.
Sponsor class: INDUSTRY
Collaborators: name: The First People's Hospital of Lianyungang
First posted: 2011-06-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is to explore the clinical efficacy of continuous Endostar infusion combined with radiotherapy in esophageal cancer patients.


Eligibility criteria: Inclusion Criteria:

* Histological or cytological diagnosis of previously untreated stage I-III esophageal cancer
* Measurable disease according to RECIST criteria
* ECOG Performance Status 0-1
* The length of esophageal carcinoma ≤ 10 cm
* Hematologic function: WBC ≥ 4.0×109/L, PLT ≥ 80×109/L, Hb ≥ 90g/L
* Renal function: Cr ≤ 2.0×UNL
* Hepatic function: BIL ≤ 2.0×UNL, ALT/AST ≤ 5.0×UNL

Exclusion Criteria:

* Pregnant or lactating women
* Evidence of bleeding diathesis, serious infection
* Serious cardiovascular disease (congestive heart failure, uncontrollable arrhythmia, unstable angina, myocardial infarction, serious heart valve disease, resistant hypertension)
* Uncontrollable mental and nervous disorders

Primary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: 1 month after treatment
Secondary outcomes:
measure: Overall Survival (OS)
timeFrame: 2 years
measure: Time to Progression (TTP)
timeFrame: every three months until disease progression
measure: Clinical Benefit Rate (CBR)
timeFrame: 1 month after treatment
measure: Serum VEGF Levels
timeFrame: at baseline and 6 weeks
measure: Incidence of Adverse Events
timeFrame: up to 3 months
Other outcomes:
Locations:
city: Lianyungang
country: China
facility: The First People's Hospital of Lianyungang
state: Jiangsu
Study officials:
affiliation: The First People's Hospital of Lianyungang
name: Xiaodong Jiang, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06667219: Influencing Factors and Interventions of Physical Exercise Behaviour of 6-Year-Old Children in Guangdong, China
Official title: Influencing Factors and Interventions of Physical Exercise Behaviour of 6-Year-Old Children in Guangdong, China
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Physical Exercise Behaviour
Fundamental Motor Skills
6-Year-Old Children
Lead sponsor: Universiti Sains Malaysia
Sponsor class: OTHER
First posted: 2024-10-31
Enrollment: 108
Sex: ALL
Minimum age (years): 6
Maximum age (years): 7
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Children will be invited to participate in the after-school physical activity experiment.This experiment will include more than 108 participants randomly assigned to the experimental group (n=54) and the control group (n=54) (randomly selected two kindergartens, one as experimental group and one as control group). All studies will be conducted in Zengcheng Kindergarten, Guangdong, China. Children will participate in this study and participats (parents/guardians) will receive a prescription for childhood exercise.
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The goal of this clinical trial is to examine the relationship between children's physical exercise behavior and children's Fundamental Motor Skills (FMS) before and after changing the influencing factors of 6-year-old children's physical exercise behavior in Guangdong Province, China. The main question it aims to answer is:

Is there any change of the relationship (time, group, and interaction) between 6-year-old children's physical exercise behaviour and children's Fundamental Motor Skills (FMS) before and after the physical activity intervention of the influencing factors in Guangdong Province, China?

Participants will:

Intervention group, Length: 12 weeks, 40 minutes, twice a week. The intervention will be conducted using a relevant physical fitness training program.

Control group, Length: 12 weeks. Content: Physical exercise using kindergarten standards.

Researchers will compare the data before and after the intervention to know whether the Fundamental Motor Skills (FMS) of 6-year-old children have changed.


Eligibility criteria: Inclusion Criteria:

* Preschool children aged 6 years old in Guangdong, China;
* Children who are of Chinese nationality;
* Male and female;
* Parents/guardians signed an informed consent form;

Exclusion Criteria:

* Have a mental illness with cognitive impairment problems;
* Children with speech or ear function impairment;
* Recent or imminent surgery (within 3 months), or medical co-morbidities;
* Parents/guardians did not sign the informed consent.

Primary outcomes:
measure: Changes in test values of 13 indicators of Fundmental Motor Skills in 6-year-old children at 12 weeks
timeFrame: 5 months
Secondary outcomes:
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Guangzhou Huali College
state: Guangdong
Study officials:
References:
Clinical trial NCT03877419: Comparison of Different Drilling Speed to Classify Bone Quality by Tactile Sensation on a Saw Bone Model
Official title: Comparison of Different Drilling Speed to Classify Bone Quality by Tactile Sensation on a Saw Bone Model
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Missing Teeth
Dental Implant
Keywords: dental implant
bone quality
tactile sensation
drilling speed
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2019-03-15
Enrollment: 40
Sex: ALL
Minimum age (years): 24
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: junior residents in NTUH

Brief summary: Comparison of different drilling speed to classify bone quality by tactile sensation on a saw bone model

Detailed description: Bone quality is one of the major factors influencing the dental implant survival rate. Bone quality is believed to have effects on initial implant stability and success of osseointegration. Different implant designs and surgical protocols were developed for improving the survival rate in different bone quality. Although bone quality can be partly diagnosed by radiographic images, lots of experienced surgeons also evaluate bone quality with tactile sensation when they drill the bone. However, variations in evaluation of bone density maybe exist among different surgeons. The drilling speed also may have effect on the outcome of evaluation. For less experienced dentists, it is difficult to diagnose bone quality with tactile sensation in the beginning. The purpose of this study is to find proper drilling speed to classify bone quality by tactile sensation on a saw bone model. Saw bones of variant densities are used as training \& testing materials. The proper drilling speed to distinguish different bone quality will be evaluated and offered to junior dentists for better implant treatment outcome.

Eligibility criteria: Inclusion Criteria:

* Adult dentist, with license no more than 5 years
* No clinical implant surgery experience or with experience less than 10 implants.

Exclusion Criteria:

-Subject who couldn't hold the test procedure

Primary outcomes:
measure: Units on a Visual Analog Score for bone density
timeFrame: 30 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
state: Test2
Study officials:
affiliation: NTUH
name: Tong-Mei Wang, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02052219: BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
Official title: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: IgA Nephropathy
Keywords: Blisibimod
IgA nephropathy
BAFF
BLyS
Lead sponsor: Anthera Pharmaceuticals
Sponsor class: INDUSTRY
First posted: 2014-02-03
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older.
* Biopsy-proven IgA nephropathy
* Proteinuria ≥ 2g/24hr or equivalent
* Receiving physician-directed optimized standard of care that includes ACEI and/or ARB.
* Estimated glomerular filtration rate (eGFR) \>40mL/min/1.73m2

Exclusion Criteria:

* Clinical or histologic evidence of non-IgA-related glomerulonephritis
* IgA nephropathy with greater than 50% glomerulosclerosis or cortical scarring
* Meets eGFR criteria
* Malignancy within past 5 years
* Known to be positive for HIV and/or positive at the screening visit for hepatitis B, or hepatitis C
* Liver disease
* Neutropenia
* Active infection requiring hospitalization or treatment with parenteral antibiotics within the past 60 days or history of repeated herpetic viral infections
* History of active tuberculosis or a history of tuberculosis infection
* Pregnant or nursing

Primary outcomes:
measure: The proportion of subjects to achieve the proteinuria threshold
timeFrame: Week 24
measure: The proportion of subjects who progress to end-stage renal disease
timeFrame: approximately 5 years
Secondary outcomes:
measure: Change from baseline in serum immunoglobulins IgA, IgG and IgM, plasma cells and B cell subsets
timeFrame: Week 24
measure: Number of Participants with Adverse Events
timeFrame: Week 24
measure: Change from baseline in serum creatinine
timeFrame: Week 24
measure: Change from baseline in eGFR
timeFrame: Week 24
measure: The proportion of subjects requiring the addition of corticosteroid or other therapy
timeFrame: Week 24
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01549119: Phase I/IIa Dose-escalation Clinical Study of VAC-3S
Official title: Multicentre, Randomized, Placebo-controlled, Double-blind, Phase I/IIa Dose-escalation Clinical Study of a Therapeutic Vaccine (VAC-3S) Intended to Confer Protection Against Immunopathological Effects of HIV-1 in Infected Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: HIV-1 Infection
Keywords: HIV-1
HIV
immunotherapy
active immunotherapy
vaccine
virulence
innate immunity
NK cells
Lead sponsor: InnaVirVax
Sponsor class: INDUSTRY
First posted: 2012-03-08
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this trial is to evaluate the safety and immunogenicity of the therapeutic vaccine candidate VAC-3S in HIV-1 infected patients under AntiRetroviral Therapy (ART) with undetectable viral loads.


Eligibility criteria: Inclusion Criteria:

* HIV-1 infected patient
* Age between 18 and 55 years
* ART (AntiRetroviral Therapy) initiation 1 year ago
* Plasma HIV RNA below 50 copies per ml on three sequential occasions including V-1 in the past 12 months
* CD4 T cell count above or equal to 200 cells per mm3,
* Nadir CD4 T cell count above or equal to 100 cells per mm3,
* Contraception in women with child-bearing potential

Exclusion Criteria:

* Any ART change within a month preceding screening.
* Chronic active liver disease, HIV-Hepatitis Coinfection.
* Immunotherapy in the past year, immunosuppressive treatment within the past month.
* History of auto-immune disease

Primary outcomes:
measure: Number of Study Participants Who Tolerated three vaccinations with VAC-3S at 4-weeks apart Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.
timeFrame: from D0 to week 24
Secondary outcomes:
measure: Anti-3S antibody titers
timeFrame: from D0 to week 60
measure: Number of Study Participants Who Tolerated three vaccinations with VAC-3S at 4-weeks apart Determined by Safety Parameter Changes According to the DAIDS (Division of Acquired Immunodeficiency Syndrome) Adverse Events (AE) Grading Table.
timeFrame: from week 24 to week 60
measure: NKp44L expression on the surface of CD4+ T lymphocytes
timeFrame: from D0 to week 60
measure: Markers of progression to AIDS. Markers include CD4+ cell count, viral load, and phenotypic markers of lymphocyte differentiation and activation.
timeFrame: from D0 to week 60
Other outcomes:
Locations:
city: Paris
country: France
facility: Hopital Pitie Salpetriere
city: Paris
country: France
facility: CIC Cochin Pasteur
Study officials:
affiliation: InnaVirVax
name: Raphael Ho Tsong Fang, DVM, PHD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01599741: X-ray Dose Reduction Study for Endovascular Interventional Radiology
Official title: Clinical Validation and Evaluation of X-ray Image Processing for Endovascular Digital Subtraction Angiography and Intervention
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Cardiovascular Disease
Keywords: X-rays
Endovascular angiography
Image processing
Lead sponsor: Philips Clinical & Medical Affairs Global
Sponsor class: INDUSTRY
First posted: 2012-05-16
Enrollment: 51
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Primary purpose: TREATMENT

Brief summary: ClarityIQ is a novel X-ray imaging technology, that combines advanced real-time image noise reduction algorithms, with state-of-the-art hardware to reduce patient entrance dose significantly. This is realized by anatomy-specific optimization of the full acquisition chain (grid switch, beam filtering, pulse width, spot size, detector and image processing engine) for every clinical task individually. Furthermore, smaller focal spot sizes, shorter pulses and the introduction of automatic real-time motion compensation in subtraction imaging are used, which are known to positively influence image quality . The final effect on the clinical image quality in peripheral angiography is investigated in this study.

Detailed description: X-ray dose and image quality are related by laws of physics. Low dose and high image quality cannot be achieved at the same time. However, image processing algorithms can help an x-ray system to acquire images with lower dose without influencing image quality or achieving higher image quality with equal dose. The primary aim of this study is to verify if the diagnostic image quality is equal or better when using a significant reduction in X-ray dose for endovascular digital subtraction angiography in combination with a novel imaging technology compared to using normal dose with conventional image technology.

Eligibility criteria: Inclusion Criteria:

* Patients older than 18 years of age undergoing digital subtraction angiography for diagnosis or treatment of iliac artery disease.

Exclusion Criteria:

* Patients not willing or unable to give consent to participate
* Patients already involved in a clinical trial
* Patients under the age of 18
* Pregnant or breastfeeding women
* Patients with kidney disease (eGFR \< 60)

Primary outcomes:
measure: Image Quality
timeFrame: 1 Day
Secondary outcomes:
measure: Radiation Dose Measurements: Dose Area Product (DAP)
timeFrame: Participants were followed for the duration of the procedure
measure: Radiation Dose Measurements: Air Kerma (AK)
timeFrame: Participants were followed for the duration of the procedure
Other outcomes:
Locations:
city: Nieuwegein
country: Netherlands
facility: St. Antonius Ziekenhuis
Study officials:
affiliation: St. Antonius Hospital
name: Marco van Strijen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06996041: Chocking First Aid Management Program for Health Care Support Workers.
Official title: Effect of Chocking First Aid Management Program on Knowledge, Attitude and Practice of Health Care Support Workers.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Choking
Keywords: Knowledge
Attitude
Practice
Chocking first aid
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2025-05-30
Enrollment: 45
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: To determine the effect of chocking first aid awareness program on knowledge, attitude and practice of health care support workers. Despite the importance of first aid skills, there may be gaps in the knowledge of healthcare support workers regarding choking management. A well-designed program can address these gaps, ensuring that workers are aware of the latest guidelines and techniques for managing choking incidents.

Knowledge and attitudes alone are not sufficient; practical skills are crucial. The program aims to translate theoretical knowledge and positive attitudes into effective practice. Training can enhance the workers\&#39; ability to perform first aid procedures correctly and confidently.

Detailed description: It is very important for every person in the community to know about first aid training to save lives and improve the overall quality of community health. Health care professionals and trainees are expected to know about it, as they frequently face life threatening situations in their daily practice.

Eligibility criteria: Inclusion Criteria:

* Physical Therapist
* Pharmacists
* Lab Technicians
* Minimum 1 Year of Practice

Exclusion Criteria:

* Unwilling
* Any upper-limb MSK problem
* Recent certification on emergency management

Primary outcomes:
measure: Knowledge, Attitude and Practice of Chocking first aid
timeFrame: 2 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Peshawar
country: Pakistan
facility: Northwest General Hospital & Research Center and Northwest Institute Of Health Sciences
state: KPK
Study officials:
affiliation: Riphah International University
name: Mehwish Waseem, MS-CPPT PhD*
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03426241: Effect of Smoking on the Expression of Gelatinases in Chronic Periodontitis
Official title: The Effect of Smoking on the Expression of Gelatinases in Chronic Periodontitis: A Cross-sectional Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontitis
Smoking
Keywords: chronic periodontitis
smoking
mmp-2
mmp-9
Lead sponsor: Baskent University
Sponsor class: OTHER
First posted: 2018-02-08
Enrollment: 80
Sex: ALL
Minimum age (years): 16
Maximum age (years): 62
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: A total of 80 subjects (35 females, 45 males, with an age range of 16-62 years) were included in this study from those patients seeking dental treatment at the Baskent University School of Dentistry

Brief summary: This study comparatively evaluate the expressions of MMP-2 and MMP-9 in smoker vs non-smoker chronic periodontitis patients as well as periodontally healthy subjects. the hypothesis of this study was that smoking may interfere with periodontal disease by effecting MMP-2 and MMP-9 expressions.

Detailed description: Smokers have greater risk for developing periodontal disease and smoking is highly correlated with greater marginal bone loss. Matrix metalloproteinases (MMP) play a major role in periodontal tissue destruction. MMP-2 and MMP-9, called gelatinases, are one of the major MMPs that plays important roles in periodontitis. To date, several studies showed the increased levels of gelatinases in periodontal disease and only a limited number of study investigated the effect of smoking on gelatinases. However, no previous study has directly investigated the possible relationship between smoking and gingival tissue gelatinases expressions (MMP-2 and MMP-9) in chronic periodontitis (CP) patients relative to periodontally healthy subjects.

Therefore this study is conducted to comparatively evaluate the expressions of MMP-2 and MMP-9 in smoker vs non-smoker chronic periodontitis patients as well as periodontally healthy subjects. the of this study hypothesis was that smoking may interfere with periodontal disease by effecting MMP-2 and MMP-9 expressions.

Eligibility criteria: Inclusion Criteria:

* A total of 80 subjects (35 females, 45 males, with an age range of 16-62 years) were included in this study from those patients seeking dental treatment at the Baskent University School of Dentistry between February 2010 and December 2012.

Exclusion Criteria:

* Patients with systemic disease;
* pregnant and/or lactating women;
* patients taking any medications that may influence the study.

Primary outcomes:
measure: expression of gelatinases levels in gingival tissue among groups
timeFrame: day 1
Secondary outcomes:
measure: difference in probing depths among groups
timeFrame: day o
measure: difference in probing depths among groups
timeFrame: day 0
Other outcomes:
Locations:
Study officials:
References: